Kyowa Kirin KYKOF Stock
Kyowa Kirin Price Chart
Kyowa Kirin KYKOF Financial and Trading Overview
| Kyowa Kirin stock price | 14 USD |
| Previous Close | 14.05 USD |
| Open | 14.05 USD |
| Bid | 14.4 USD x 30000 |
| Ask | 16.1 USD x 40000 |
| Day's Range | 14.05 - 14.05 USD |
| 52 Week Range | 12.42 - 18 USD |
| Volume | 655 USD |
| Avg. Volume | 3.79K USD |
| Market Cap | 7.33B USD |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | 13.856436 |
| EPS (TTM) | 1.01 USD |
| Forward Dividend & Yield | 0.44 (3.16%) |
| Ex-Dividend Date | December 29, 2026 |
| 1y Target Est | N/A |
KYKOF Valuation Measures
| Enterprise Value | -257755414528 USD |
| Trailing P/E | 13.856436 |
| Forward P/E | 14.578125 |
| PEG Ratio (5 yr expected) | 4.64 |
| Price/Sales (ttm) | 0.013830841 |
| Price/Book (mrq) | 1.2548012 |
| Enterprise Value/Revenue | -0.487 |
| Enterprise Value/EBITDA | -1.865 |
Trading Information
Kyowa Kirin Stock Price History
| Beta (5Y Monthly) | 0.22 |
| 52-Week Change | -17.98% |
| S&P500 52-Week Change | 14.57% |
| 52 Week High | 18 USD |
| 52 Week Low | 12.42 USD |
| 50-Day Moving Average | 14.74 USD |
| 200-Day Moving Average | 14.72 USD |
KYKOF Share Statistics
| Avg. Volume (3 month) | 3.79K USD |
| Avg. Daily Volume (10-Days) | 21.97K USD |
| Shares Outstanding | 523.59M |
| Float | 229.5M |
| Short Ratio | N/A |
| % Held by Insiders | 55.72% |
| % Held by Institutions | 18.08% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 67 |
| Trailing Annual Dividend Yield | 476.86% |
| 5 Year Average Dividend Yield | 204.00% |
| Payout Ratio | 0.4312 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 15.35% |
| Operating Margin (ttm) | 10.02% |
| Gross Margin | 75.00% |
| EBITDA Margin | 26.08% |
Management Effectiveness
| Return on Assets (ttm) | 6.19% |
| Return on Equity (ttm) | 9.25% |
Income Statement
| Revenue (ttm) | 529.8B USD |
| Revenue Per Share (ttm) | 1012.02 USD |
| Quarterly Revenue Growth (yoy) | 15.29% |
| Gross Profit (ttm) | 397.38B USD |
| EBITDA | 138.22B USD |
| Net Income Avi to Common (ttm) | 81.34B USD |
| Diluted EPS (ttm) | 1.01 |
| Quarterly Earnings Growth (yoy) | 83.00% |
Balance Sheet
| Total Cash (mrq) | 265.08B USD |
| Total Cash Per Share (mrq) | 506.28 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.839 |
| Book Value Per Share (mrq) | 11.153161 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 138.11B USD |
| Levered Free Cash Flow (ttm) | 30.9B USD |
Profile of Kyowa Kirin
| Country | United States |
| State | N/A |
| City | Chiyoda |
| Address | Otemachi Financial City Grand Cube |
| ZIP | 100-0004 |
| Phone | 81 3 5205 7200 |
| Website | https://www.kyowakirin.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 5173 |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Q&A For Kyowa Kirin Stock
What is a current KYKOF stock price?
Kyowa Kirin KYKOF stock price today per share is 14 USD.
How to purchase Kyowa Kirin stock?
You can buy KYKOF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kyowa Kirin?
The stock symbol or ticker of Kyowa Kirin is KYKOF.
Which industry does the Kyowa Kirin company belong to?
The Kyowa Kirin industry is Drug Manufacturers - Specialty & Generic.
How many shares does Kyowa Kirin have in circulation?
The max supply of Kyowa Kirin shares is 523.59M.
What is Kyowa Kirin Price to Earnings Ratio (PE Ratio)?
Kyowa Kirin PE Ratio is 13.85643600 now.
What was Kyowa Kirin earnings per share over the trailing 12 months (TTM)?
Kyowa Kirin EPS is 1.01 USD over the trailing 12 months.
Which sector does the Kyowa Kirin company belong to?
The Kyowa Kirin sector is Healthcare.
